Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 93 | EYES2023 | Next issue

ESE Young Endocrinologists and Scientists (EYES) 2023

ESE Young Endocrinologists and Scientists (EYES) 2023

Oral communication 3: Adrenal Tumors and Neuroendocrine Tumors

ea0093oc15 | Oral communication 3: Adrenal Tumors and Neuroendocrine Tumors | EYES2023

Targeting the ferroptosis-macrophage crosstalk in adrenocortical carcinoma

Triebig Alexandra , Weigand Isabel , Atici Sena , Angeli Jose Pedro Friedmann , Kroisz Matthias

Background: Ferroptosis is an emerging form of regulated necrotic cell death characterized by excessive lipid peroxidation. Adrenocortical carcinoma (ACC) cells have been shown to be highly susceptible to ferroptosis caused by active steroid hormone synthesis. While therapeutic activation of ferroptosis has been proposed as a novel treatment strategy, its impact on the tumor immune microenvironment (TIME) remains elusive. Macrophages are an important TIME component and modulat...

ea0093oc16 | Oral communication 3: Adrenal Tumors and Neuroendocrine Tumors | EYES2023

Bone fragility in well-differentiated gastroenteropancreatic-neuroendocrine tumors: Results from a retrospective two-centered study

Brunetti Alessandro , Jaafar Simona , Chiardi Isabella , Cellini Miriam , Salcuni Antonio Stefano , Pigni Stella , Lavezzi Elisabetta , Lania Andrea , Mazziotti Gherardo , Vescini Fabio

Background: Patients affected by gastroenteropancreatic-neuroendocrine tumors (GEP-NETs) present an increased risk of bone fragility due to several factors, such as bone metastases, vitamin D deficiency, hormonal secretion, medical and surgical treatments. Although patients with well-differentiated GEP-NETs generally present a long life-expectancy, occurrence of fragility fractures could significantly impair quality of life.Objectives: The study aims to ...

ea0093oc17 | Oral communication 3: Adrenal Tumors and Neuroendocrine Tumors | EYES2023

Preclinical and clinical evidence of progesterone/megestrol acetate activity in metastatic adrenocortical carcinoma

Tamburello Mariangela , Abate Andrea , Turla Antonella , Lagana Marta , Rossini Elisa , Hantel Constanze , Tiberio Guido Alberto Massimo , Cosentini Deborah , Grisanti Salvatore , Berruti Alfredo , Sigala Sandra

Background: Adrenocortical carcinoma (ACC) is a rare cancer for which available systemic treatments, mitotane ± etoposide, doxorubicin and cisplatin (EDP-M), have limited efficacy.Objectives: Here, we strengthen the effect of progesterone (Pg) on metastatic ACC cell lines, studying whether it could influence growth, invasiveness, and metastasis formation. Additionally, we investigate if the Pg analogue megestrol-acetate administered with EDP-M could...

ea0093oc18 | Oral communication 3: Adrenal Tumors and Neuroendocrine Tumors | EYES2023

Towards an understanding of the microenvironment of ACC: Impact of steroid hormones and driver pathways

Maier Tanja , Landwehr Laura-Sophie , Sbiera Silviu , Schauer Marc P. , Schwarzmuller Paul , Fassnacht Martin , Kroisz Matthias

Background: Immune checkpoint therapy response rate in adrenocortical carcinoma (ACC) is only ~15%. Glucocorticoid (GC) secretion is present in ~60% of tumours, associated with adverse outcome and has been associated with an immunologically cold tumoural microenvironment. On the other hand, activation of the Wnt/ß-Catenin pathway has been suggested to contribute to reduced immune infiltration.Aims: First, we aim to improve the understanding of cellu...

ea0093oc19 | Oral communication 3: Adrenal Tumors and Neuroendocrine Tumors | EYES2023

FGF/FGFR signaling in adrenocortical tumorigenesis: Novel potential therapeutic targets in adrenocortical carcinoma

Kappenstein Lena , Paul Alexander , Altieri Barbara , Sbiera Iuliu , Sandra Sigala , Alfredo Berruti , Fassnacht Martin , Sbiera Silviu , Tamburello Mariangela

Background: Adrenocortical carcinoma (ACC) is one of the most aggressive endocrine malignancies. The Fibroblast Growth Factor/Fibroblast Growth Factor Receptor (FGF/FGFR) pathway plays a role in both embryogenesis and tumorigenesis of adrenal gland. Our group demonstrated that FGFR1-4 were upregulated in ACCs and that their high expression was significantly associated with worse prognosis, suggesting that they are potentially interesting therapeutic targets.<p class="abste...

ea0093oc20 | Oral communication 3: Adrenal Tumors and Neuroendocrine Tumors | EYES2023

ROR-1 specific CAR-T cells with CRISPR/CAS9 mediated glucocorticoid receptor-knockout exert potent antitumor efficacy in advanced adrenocortical carcinoma

Schauer Marc Philipp , Altieri Barbara , Redondo-Frutos Rodrigo A , Spieler Peter , Maier Tanja , Oppelt Daniel , Kroiss Matthias , Sbiera Silviu , Weber Justus , Fassnacht Martin , Landwehr Laura-Sophie , Hudecek Michael

# These authors contributed equallyIntroduction: Adrenocortical carcinoma (ACC) is a rare and aggressive endocrine malignancy with poor prognosis and limited treatment options. In addition, ACC is characterized by endogenous glucocorticoid (GC) excess in 60% of cases which is hypothesized to be one reason, why first clinical trials evaluating the potency of immune checkpoint blockade showed only modest results. Here, we report the identificati...

ea0093oc21 | Oral communication 3: Adrenal Tumors and Neuroendocrine Tumors | EYES2023

Identification of adrenocortical masses malignancy through radiomics: A pilot study

Tucci Lorenzo , Vara Giulio , Improta Ilaria , De Leo Antonio , Selva Saverio , Balacchi Caterina , Santini Donatella , Mosconi Cristina , Vicennati Valentina , Pagotto Uberto , Di Dalmazi Guido

Background: Adrenal lipid poor adenoma (LPA) and adrenocortical cancer (ACC) may overlap in computerized tomography (CT). Radiomics recently emerged as new tool for malignant behavior identification.Aim: To assess radiomics utility for identification of ACC and LPA in adrenocortical masses with unenhanced (UE) CT scan attenuationā‰„10 Hounsfield Unit (HU).Methods: We retrospectively enrolled 50 patients, 38 radiologically defin...